ARTICLE | Clinical News
Deltyba delamanid regulatory update
May 5, 2014 7:00 AM UTC
The European Commission granted conditional approval to Deltyba delamanid from Otsuka to treat pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults when alternative treatments cannot be used due to resistance or intolerance. Otsuka plans to launch the nitro-dihydro-imidazooxazole derivative in the EU in 4-6 weeks (see BioCentury, Nov. 25, 2013). ...